Markets:

Overview

News

Currencies

International

Treasuries

Oruka Therapeutics, Inc. - Common Stock (NQ:ORKA)

100.34 +4.91 (+5.15%)

Delayed Quote Updated: 11:12 AM EST, Nov 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Oruka Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

February 09, 2026

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

January 12, 2026

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Oruka Therapeutics, Inc.

Via GlobeNewswire

MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades ↗

September 29, 2025

Via Stocktwits

Oruka Therapeutics Announces New Board Member and Board Transition

December 11, 2025

Appoints accomplished commercial leader Chris Martin to its Board of Directors

From Oruka Therapeutics, Inc.

Via GlobeNewswire

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

November 13, 2025

Via Benzinga

AutoZone To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday ↗

November 13, 2025

Via Benzinga

Oruka Therapeutics Inc (NASDAQ:ORKA) Reports Q3 2025 Results, Beats EPS Estimates and Provides Clinical Pipeline Updates ↗

November 12, 2025

Oruka Therapeutics reports Q3 2025 results, beating EPS estimates. With a strong $500.9M cash position, the biotech advances its clinical pipeline for ORKA-001 and ORKA-002.

Via Chartmill

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 12, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

The Insider Report: The Bulls Can Thank Tech ↗

November 02, 2025

Via Benzinga

Oruka Therapeutics to Present at Multiple November Investor Conferences

October 29, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Stock Market Today: Nasdaq, S&P 500 Futures Rise As Government Enters 2nd Week Of Shutdown—Plug, Lithium Americas, UiPath In Focus ↗

October 06, 2025

U.S. stock futures rose on Monday following Friday’s mixed moves. Futures of major benchmark indices were higher.

Via Benzinga

Topics Stocks

Constellation Brands, Aehr Test Systems And 3 Stocks To Watch Heading Into Monday ↗

October 05, 2025

US stock futures up, focus on Constellation Brands, SkyWater Tech, Aehr Test Systems, Oruka Therapeutics and VCI Global earnings.

Via Benzinga

MoonLake Crashes 89% On Mixed Results For Skin Disease Treatment ↗

September 29, 2025

MoonLake Immunotherapeutics stock crashed Monday after the company posted mixed results for its skin disease drug.

Via Investor's Business Daily

Wednesday's session: gap up and gap down stocks ↗

September 17, 2025

Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday ↗

September 17, 2025

Via Benzinga

Oruka Therapeutics, Up 20%, Is Trying To Take On AbbVie's Biggest Moneymaker ↗

September 17, 2025

Shares skyrocketed after the company said its drug has a half-life of about 100 days.

Via Investor's Business Daily

Discover the top movers in Wednesday's pre-market session. ↗

September 17, 2025

Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 17, 2025

Via Benzinga

Why New Fortress Energy Shares Are Trading Higher By 41%; Here Are 20 Stocks Moving Premarket ↗

September 17, 2025

Via Benzinga

Oruka Therapeutics Announces $180 Million Private Placement

September 17, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

September 17, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 11, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

July 21, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

July 01, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

May 21, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

May 20, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

April 29, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

March 26, 2025

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.